Purinergic Signaling and the Postmenopausal Heart

Overseen By Robina Matyal, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Beth Israel Deaconess Medical Center

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

Trial Summary

What is the purpose of this trial?

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Research Team

Robina Matyal, MD

Principal Investigator

Beth Israel Deaconess Medical Center, Professor of Anesthesia

Simon Robson, MD, PhD

Principal Investigator

Beth Israel Deaconess Medical Center,Vice Chair Research

Eligibility Criteria

Inclusion Criteria

This applies to individuals having a cardiac surgery procedure while connected to cardiopulmonary bypass.

Treatment Details

Participant Groups

Group I: Women Experimental Treatment 1 Intervention

Women who are undergoing cardiac surgery

Group II: Men Experimental Treatment 1 Intervention

Men who are undergoing cardiac surgery

Who Is Running the Clinical Trial?

Beth Israel Deaconess Medical Center

Lead Sponsor

Trials

872

Recruited

12,930,000+